Christopher W. Cain - 23 Mar 2026 Form 4 Insider Report for Damora Therapeutics, Inc. (DMRA)

Reporting relationship: Director
Issuer ticker: DMRA
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Mar 2026, 18:01:53 UTC
Prior SEC filing: 17 Nov 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Garrett Winslow, attorney-in-fact

Key filing fact

Christopher W. Cain filed Form 4 for Damora Therapeutics, Inc. (DMRA) on 25 Mar 2026.

Key facts

This page summarizes Christopher W. Cain's Form 4 filing for Damora Therapeutics, Inc. (DMRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Mar 2026, 18:01.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817733 Primary reporting owner

CAIN CHRISTOPHER W.

Relationship: Director
Address: C/O DAMORA THERAPEUTICS, INC.,, 221 CRESCENT ST, BUILDING 23, SUITE 105, WALTHAM
Signature: /s/ Garrett Winslow, attorney-in-fact
Signature date: 25 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +37,313
Change %
Price: $0.000000^*
Shares after: 37,313
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,313
Exercise price: $23.05
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.